Table 1 (abstract P004). Outcomes of etanercept therapy for different JIA subtypes
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
Point | Oligoartritis | Polyartritis RF-negative | Polyartritis RF-positive | Enthesitis | Psoriatc arthritis | р |
|---|---|---|---|---|---|---|
Time before ETN, years | 2,2 (1,3; 4,9) | 2,4 (0,8; 5,1) | 1,6 (0,8; 3,3) | 2,1 (0,9; 4,0) | 2,6 (1,3; 4,8) | 0,767 |
Remission, n (%) | 55/69 (79,7) | 119/149 (79,9) | 14/18 (77,8) | 54/71 (76,1) | 12/15 (80,0) | 0,976 |
Time to remission, years | 0,5 (0,3; 1,3) | 0,7 (0,4; 1,4) | 0,8 (0,4; 1,3) | 0,6 (0,3; 1,2) | 0,7 (0,3; 1,6) | 0,899 |
Flare, n (%) | 13/50 (26,0) | 32/112 (28,6) | 5/16 (31,3) | 16/48 (33,3) | 4/11 (36,4) | 0,917 |
Time to flare, mounths. | 26,3 (7,0; 41,5) | 18,2 (6,0; 25,4) | 4,4 (4,0; 9,1) | 7,6 (4,7; 14,2) | 3,6 (3,0; 10,5) | 0,050 |
Change of biological therapy | 7/59 (11,9) | 21/128 (16,4) | 3/18 (16,7) | 13/61 (21,3) | 3/14 (21,4) | 0,709 |